Look for airless pumps or opaque, airtight containers
Song J, Zhong C, Bonaguidi MA, Sun GJ, Hsu D, Gu Y, et al
Because subtherapeutic dosing sits below the FDA-approved starting dose and lacks randomized trial support, providers will explain the trade-offs honestly: the appeal (slower onset, reduced GI side-effect reports, lower cost) and the limits (no efficacy guarantee, no proven cardiovascular benefit at microdose levels, ongoing safety monitoring still required)
Understanding how to reconstitute tirzepatide properly is essential for anyone using compounded formulations, as improper reconstitution can lead to inaccurate dosing that makes side effect management unpredictable
2019;29(2):320-334.e5